Olfr151 inhibitors are a distinct class of chemical compounds developed to specifically target and inhibit the activity of the Olfr151 protein, an olfactory receptor that belongs to the extensive G-protein-coupled receptor (GPCR) superfamily. Olfactory receptors like Olfr151 are essential for the detection and transduction of odorant signals, playing a critical role in the sense of smell. These receptors are situated in the membranes of olfactory sensory neurons within the nasal epithelium, where they interact with specific odorant molecules from the environment. Upon binding an odorant, Olfr151 undergoes a conformational change that activates an intracellular signaling cascade, leading to the generation of an electrical signal that is transmitted to the brain, ultimately contributing to the perception of smell. Inhibitors of Olfr151 are small molecules designed to bind to the receptor's odorant-binding pocket or other key functional regions, effectively blocking the receptor's interaction with its natural ligands. This inhibition prevents the receptor from initiating the signaling processes that are essential for olfactory perception.
The development of Olfr151 inhibitors involves a detailed investigation of the receptor's structural and functional properties, with an emphasis on identifying and characterizing its binding sites and the molecular interactions critical for its activity. Researchers often use high-throughput screening methods to discover lead compounds that exhibit potential inhibitory effects against Olfr151. These lead compounds are subsequently optimized through structure-activity relationship (SAR) studies, which focus on refining their chemical structures to improve binding affinity, specificity, and overall stability. The chemical structures of Olfr151 inhibitors are typically diverse, incorporating functional groups that enable strong and specific interactions with the receptor, such as hydrogen bonds, hydrophobic contacts, and van der Waals forces. Structural biology techniques like X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy are employed to visualize these interactions at an atomic level, providing valuable insights that guide the refinement and development of these inhibitors. Achieving high selectivity is a critical objective in the design of Olfr151 inhibitors, ensuring that these compounds specifically target Olfr151 without affecting other olfactory receptors or GPCRs with similar structural features. This selectivity is crucial for enabling precise modulation of Olfr151 activity, allowing researchers to investigate its specific role in olfactory perception and to deepen their understanding of the molecular mechanisms underlying the sense of smell.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Adenylyl cyclase activator, may indirectly influence GPCR signaling pathways including Olfr151. | ||||||
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
Beta-adrenergic antagonist, might modulate GPCR activity potentially affecting Olfr151. | ||||||
Carvedilol | 72956-09-3 | sc-200157 sc-200157A sc-200157B sc-200157C sc-200157D | 100 mg 1 g 10 g 25 g 100 g | $122.00 $235.00 $520.00 $979.00 $1500.00 | 2 | |
Beta-adrenergic antagonist with alpha-1 blocking activity, could influence Olfr151 signaling. | ||||||
Yohimbine hydrochloride | 65-19-0 | sc-204412 sc-204412A sc-204412B | 1 g 5 g 25 g | $50.00 $168.00 $520.00 | 2 | |
Alpha-2 adrenergic receptor antagonist, may affect GPCR signaling pathways related to Olfr151. | ||||||
Labetalol | 36894-69-6 | sc-484723 | 50 mg | $176.00 | ||
Combined alpha and beta blocker, could indirectly affect GPCR pathways including Olfr151. | ||||||
Pindolol | 13523-86-9 | sc-204847 sc-204847A | 100 mg 1 g | $194.00 $760.00 | ||
Beta-adrenergic antagonist, may influence GPCR-mediated signaling pathways related to Olfr151. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $27.00 $37.00 | 5 | |
Beta-adrenergic agonist, could indirectly affect Olfr151 through GPCR modulation. | ||||||
Atropine | 51-55-8 | sc-252392 | 5 g | $200.00 | 2 | |
Muscarinic acetylcholine receptor antagonist, may influence GPCR signaling pathways including Olfr151. | ||||||
Salmeterol | 89365-50-4 | sc-224277 sc-224277A | 10 mg 50 mg | $186.00 $562.00 | 1 | |
Beta-2 adrenergic agonist, potentially affecting GPCR pathways related to Olfr151. | ||||||
Alprenolol | 13655-52-2 | sc-507469 | 50 mg | $130.00 | ||
Beta blocker, could indirectly influence GPCR signaling pathways including Olfr151. | ||||||